Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Aclaris Therapeutics, Inc. clinical trials
The registry lists 33 studies whose lead sponsor is Aclaris Therapeutics, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Aclaris Therapeutics, Inc..
- Aclaris Therapeutics, Inc.33 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 33 of 33.
- ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT07011706Phase 2
- ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)CompletedNCT05279417Phase 2
- Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic DermatitisCompletedNCT06585202Phase 2
- ATI-450 vs Placebo in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)CompletedNCT05216224Phase 2
- Study of ATI-450 vs Placebo in Patients With Moderate to Severe Psoriatic ArthritisTerminatedNCT05511519Phase 2
- Study of ATI-1777 in Patients 12 to 65 Years Old With Mild to Severe Atopic DermatitisCompletedNCT05432596Phase 2
- Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic DermatitisCompletedNCT04598269Phase 2
- Study of ATI-450 in Patients With Cryopyrin-Associated Periodic Syndrome (CAPS)TerminatedNCT04524858Phase 2
- Study of ATI-450 Plus Methotrexate (MTX) vs MTX Alone in Patients With Moderate to Severe RACompletedNCT04247815Phase 2
- A Study in Male and Female Subjects With Androgenetic Alopecia Treated With ATI-50002 Topical SolutionCompletedNCT03495817Phase 2
- Study of A-101 for the Treatment of Seborrheic KeratosisCompletedNCT02260180Phase 2
- A Study of ATI-50002 Topical Solution for the Treatment of VitiligoCompletedNCT03468855Phase 2
- Safety Study of A-101 Topical Solution for the Treatment of Common WartsCompletedNCT03812510Phase 3
- A Study of A-101 Topical Solution for the Treatment of Common WartsCompletedNCT03691831Phase 3
- ATI-502 Topical Solution for the Treatment of Alopecia Areata (AA), Alopecia Universalis (AU) and Alopecia Totalis (AT)TerminatedNCT03759340Phase 2
- Study of A-101 Topical Solution for the Treatment of Common WartsCompletedNCT03687372Phase 3
- ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia TotalisCompletedNCT03594227Phase 2
- Safety and Pharmacokinetic Study of ATI-50002 in Subjects With Alopecia Universalis (AU) and Alopecia Totalis (AT)CompletedNCT03315689Phase 2
- A Study of ATI-50002 Topical Solution for the Treatment of Alopecia AreataTerminatedNCT03354637Phase 2
- A Study of A-101 Topical Solution in Subjects With Dermatosis Papulosa NigraCompletedNCT03224598Phase 2
- A Study of ATI-502 Topical Solution for the Treatment of Atopic DermatitisCompletedNCT03585296Phase 2
- Open Label Study of ATI-50002 Topical Solution Administered to Adult Subjects With Eyebrow Loss Due to Alopecia AreataCompletedNCT03551821Phase 2
- An A Study Assessing Subject Satisfaction With A-101 Topical Solution for Seborrheic KeratosesCompletedNCT03487588Phase 4
- Safety and Tolerability of Oxymetazoline and Energy-Based Therapy in Participants With RosaceaCompletedNCT03380390Phase 4
- A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic KeratosisCompletedNCT03148691Phase 2
- A Phase2 of A-101 Topical Solution in Subjects With Common WartsCompletedNCT03210337Phase 2
- A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common WartsCompletedNCT03278028Phase 2
- Dose-Response Profile of A-101 in Subjects With Seborrheic KeratosisCompletedNCT02160626Phase 2
- Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic KeratosisCompletedNCT01986920Phase 1/2
- A Study of A-101 Solution in Subjects With Common Warts.CompletedNCT02669862Phase 2
- An Open-Label Safety Study of A-101 SolutionCompletedNCT02667288Phase 3
- A Study of A-101 Solution 40% in Subjects With Seborrheic Keratosis.CompletedNCT02667236Phase 3
- A Randomized, Double-Blind, Vehicle-Controlled Study in Subjects With Seborrheic KeratosisCompletedNCT02667275Phase 3